IBI112
As of the edition of 20 October 2026, IBI112 is a drug known only by a code name: in active development; acts on IL23A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2025
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL23A | Interleukin-23 subunit alpha | Q9NPF7 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 3 | 2 | 1 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innovent Biologics | Lead sponsor of trials | 2021 to now |
| Innovent Biopharmaceutical Technology | Lead sponsor of trials | 2025 to now |